BioMatrix Specialty Infusion Pharmacy’s Post

Guselkumab, a targeted inhibitor of interleukin-23, has emerged as a promising therapy for psoriatic arthritis, offering hope for improved patient outcomes. The study demonstrated the 6-month real-world effectiveness of guselkumab in treating PsA patients with a history of active, long-standing disease, previous bDMARD therapy, and comorbidities. The relatively high DRR over 18 months was not influenced by disease duration, comorbidities, obesity, or previous bDMARD treatment. Read more on MD Newsline https://lnkd.in/gEhyW_Mk

#liverdisease #medicine #medicalscience #treatment #review https://lnkd.in/dzTic-wY Abstract Importance: Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of #cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people. Observations: The most common causes of cirrhosis in the US, which can overlap, include #alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic #fatty #liver disease (26%), and #hepatitis C (41%).             Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.

John Dirk Vestergaard Nieland presents: This article introduces a novel neurometabolic framework, advocating a systemic approach to understanding and treating neurodegenerative diseases by focusing on metabolic dysfunctions at their core. #ALS #MultipleSclerosis #Alzheimers 

John Dirk Vestergaard Nieland presents: This article introduces a novel neurometabolic framework, advocating a systemic approach to understanding and treating neurodegenerative diseases by focusing on metabolic dysfunctions at their core. #ALS #MultipleSclerosis #Alzheimers 

Systemic Inflammation Index [SII]= PMN# x Plt # / Lymphs# (all from CBC) has predictive value. Review of 16 studies (2893 immune pts & 2346 controls). SII significantly higher in ID vs controls, active vs remission, & those w/ & W/O immune disorders https://buff.ly/3xuA3lr

John Dirk Vestergaard Nieland presents: This article introduces a novel neurometabolic framework, advocating a systemic approach to understanding and treating neurodegenerative diseases by focusing on metabolic dysfunctions at their core. #ALS #MultipleSclerosis #Alzheimers 

Systemic Inflammation Index [SII]= PMN# x Plt # / Lymphs# (all from CBC) has predictive value. Review of 16 studies (2893 immune pts & 2346 controls). SII significantly higher in ID vs controls, active vs remission, & those w/ & W/O immune disorders https://buff.ly/3THT1MZ

John Dirk Vestergaard Nieland presents: This article introduces a novel neurometabolic framework, advocating a systemic approach to understanding and treating neurodegenerative diseases by focusing on metabolic dysfunctions at their core. #ALS #MultipleSclerosis #Alzheimers 

NEJM: Trial of Lixisenatide in Early Parkinson’s Disease https://lnkd.in/dS_yKicJ https://lnkd.in/dcHCQmG2 BACKGROUND Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. METHODS In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson’s disease. Participants in whom Parkinson’s disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by −0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P=0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS In participants with early Parkinson’s disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson’s disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.)

Problems in Blood Brain Barrier.. a trigger or a consequence of Central Nervous diseases.. more #updated information in this article review... a good read, surely needs more than 2 minutes.